These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

217 related items for PubMed ID: 30364187

  • 1. Class-B CpG-ODN Formulated With a Nanostructure Induces Type I Interferons-Dependent and CD4+ T Cell-Independent CD8+ T-Cell Response Against Unconjugated Protein Antigen.
    Chiodetti AL, Sánchez Vallecillo MF, Dolina JS, Crespo MI, Marin C, Schoenberger SP, Allemandi DA, Palma SD, Pistoresi-Palencia MC, Morón G, Maletto BA.
    Front Immunol; 2018; 9():2319. PubMed ID: 30364187
    [Abstract] [Full Text] [Related]

  • 2. Adjuvant activity of CpG-ODN formulated as a liquid crystal.
    Sánchez Vallecillo MF, Ullio Gamboa GV, Palma SD, Harman MF, Chiodetti AL, Morón G, Allemandi DA, Pistoresi-Palencia MC, Maletto BA.
    Biomaterials; 2014 Mar; 35(8):2529-42. PubMed ID: 24382332
    [Abstract] [Full Text] [Related]

  • 3. Polymeric antigen BLSOmp31 formulated with class B CpG-ODN in a nanostructure (BLSOmp31/CpG-ODN/Coa-ASC16) administered by parenteral or mucosal routes confers protection against Brucella ovis in Balb/c mice.
    Moran MC, Bence AR, Vallecillo MFS, Lützelschwab CM, Rodriguez MG, Pardo R, Goldbaum FA, Zylberman V, Palma SD, Maletto BA, Estein SM.
    Res Vet Sci; 2021 Mar; 135():217-227. PubMed ID: 33631456
    [Abstract] [Full Text] [Related]

  • 4. Corrigendum to "CpG-ODN formulated with a nanostructure as adjuvant for anticrotalic serum production. Studies in mice" [Toxicon 215 (2022) 28-36].
    Fusco LS, Pascual MM, Hernandez D, Sánchez Vallecillo MF, Arrieta MB, Moron G, Palma S, Maletto BA, Leiva LC.
    Toxicon; 2022 Sep; 216():114. PubMed ID: 35841861
    [Abstract] [Full Text] [Related]

  • 5. A liquid crystal of ascorbyl palmitate, used as vaccine platform, provides sustained release of antigen and has intrinsic pro-inflammatory and adjuvant activities which are dependent on MyD88 adaptor protein.
    Sánchez Vallecillo MF, Minguito de la Escalera MM, Aguirre MV, Ullio Gamboa GV, Palma SD, González-Cintado L, Chiodetti AL, Soldano G, Morón G, Allemandi DA, Ardavín C, Pistoresi-Palencia MC, Maletto BA.
    J Control Release; 2015 Sep 28; 214():12-22. PubMed ID: 26188153
    [Abstract] [Full Text] [Related]

  • 6. pH-Responsive nanoparticle vaccines for dual-delivery of antigens and immunostimulatory oligonucleotides.
    Wilson JT, Keller S, Manganiello MJ, Cheng C, Lee CC, Opara C, Convertine A, Stayton PS.
    ACS Nano; 2013 May 28; 7(5):3912-25. PubMed ID: 23590591
    [Abstract] [Full Text] [Related]

  • 7. Improved biodistribution and enhanced immune response of subunit vaccine using a nanostructure formed by self-assembly of ascorbyl palmitate.
    Marin C, Ruiz Moreno FN, Sánchez Vallecillo MF, Pascual MM, Dho ND, Allemandi DA, Palma SD, Pistoresi-Palencia MC, Crespo MI, Gomez CG, Morón G, Maletto BA.
    Nanomedicine; 2024 Jun 28; 58():102749. PubMed ID: 38719107
    [Abstract] [Full Text] [Related]

  • 8. Three CpG oligodeoxynucleotide classes differentially enhance antigen-specific humoral and cellular immune responses in mice.
    Liu Y, Luo X, Yang C, Yu S, Xu H.
    Vaccine; 2011 Aug 05; 29(34):5778-84. PubMed ID: 21664398
    [Abstract] [Full Text] [Related]

  • 9. Double-stranded phosphodiester cytosine-guanine oligodeoxynucleotide complexed with calcium phosphate as a potent vaccine adjuvant for activating cellular and Th1-type humoral immunities.
    Hanagata N, Li X, Chen MH, Li J, Hattori S.
    Int J Nanomedicine; 2018 Aug 05; 13():43-62. PubMed ID: 29317815
    [Abstract] [Full Text] [Related]

  • 10. Immunostimulatory Properties of Lipid Modified CpG Oligonucleotides.
    Yu C, An M, Li M, Liu H.
    Mol Pharm; 2017 Aug 07; 14(8):2815-2823. PubMed ID: 28686452
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. A Vaccine Based on Kunitz-Type Molecule Confers Protection Against Fasciola hepatica Challenge by Inducing IFN-γ and Antibody Immune Responses Through IL-17A Production.
    Silvane L, Celias DP, Romagnoli PA, Maletto BA, Sanchez Vallecillo MF, Chiapello LS, Palma SD, Allemandi DA, Sanabria REF, Pruzzo CI, Motrán CC, Cervi L.
    Front Immunol; 2020 Aug 07; 11():2087. PubMed ID: 33193292
    [Abstract] [Full Text] [Related]

  • 13. Generation of antitumor immunity by cytotoxic T lymphocyte epitope peptide vaccination, CpG-oligodeoxynucleotide adjuvant, and CTLA-4 blockade.
    Davila E, Kennedy R, Celis E.
    Cancer Res; 2003 Jun 15; 63(12):3281-8. PubMed ID: 12810660
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. The novel complex combination of alum, CpG ODN and HH2 as adjuvant in cancer vaccine effectively suppresses tumor growth in vivo.
    Tian Y, Li M, Yu C, Zhang R, Zhang X, Huang R, Lu L, Yuan F, Fan Y, Zhou B, Men K, Xu H, Yang L.
    Oncotarget; 2017 Jul 11; 8(28):45951-45964. PubMed ID: 28515346
    [Abstract] [Full Text] [Related]

  • 16. Topical CpG adjuvantation of a protein-based vaccine induces protective immunity to Listeria monocytogenes.
    Cheng WK, Wee K, Kollmann TR, Dutz JP.
    Clin Vaccine Immunol; 2014 Mar 11; 21(3):329-39. PubMed ID: 24391136
    [Abstract] [Full Text] [Related]

  • 17. Attachment of class B CpG ODN onto DOTAP/DC-chol liposome in nasal vaccine formulations augments antigen-specific immune responses in mice.
    Tada R, Muto S, Iwata T, Hidaka A, Kiyono H, Kunisawa J, Aramaki Y.
    BMC Res Notes; 2017 Jan 26; 10(1):68. PubMed ID: 28126014
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Trans-sialidase recombinant protein mixed with CpG motif-containing oligodeoxynucleotide induces protective mucosal and systemic trypanosoma cruzi immunity involving CD8+ CTL and B cell-mediated cross-priming.
    Hoft DF, Eickhoff CS, Giddings OK, Vasconcelos JR, Rodrigues MM.
    J Immunol; 2007 Nov 15; 179(10):6889-900. PubMed ID: 17982080
    [Abstract] [Full Text] [Related]

  • 20. Vaccination with heat-killed leishmania antigen or recombinant leishmanial protein and CpG oligodeoxynucleotides induces long-term memory CD4+ and CD8+ T cell responses and protection against leishmania major infection.
    Rhee EG, Mendez S, Shah JA, Wu CY, Kirman JR, Turon TN, Davey DF, Davis H, Klinman DM, Coler RN, Sacks DL, Seder RA.
    J Exp Med; 2002 Jun 17; 195(12):1565-73. PubMed ID: 12070284
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.